이평세 (Harvard Medical School / UC Berkeley)

한빛사논문

조회114

Harvard Medical School / UC Berkeley

CV File 956 kb

Nat. Commun., Aug 10 2024, 15 (1) | https://doi.org/10.1038/s41467-024-50053-1 Acoustofluidic-based therapeutic apheresis system

Mengxi Wu^1,2,10, Zhiteng Ma^2,10, Xianchen Xu², Brandon Lu³, Yuyang Gu², Janghoon Yoon⁴, Jianping Xia², Zhehan Ma³, Neil Upreti³, Imran J. Anwar⁴, Stuart J. Knechtle⁴, Eileen T. Chambers⁴, Jean Kwun⁴, Luke P. Lee^5,6,7,8,9 & Tony Jun Huang²

¹School of Mechanical Engineering, Dalian University of Technology, Dalian, Liaoning, P.R. China.

²Thomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.

³Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.

⁴Department of Surgery, Duke Transplant Center, Duke University Medical Center, Durham, NC 27708, USA.

⁵Renal Division and Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Harvard University, Brigham and Women’s Hospital, Boston, MA 02115, USA.

⁶Department of Bioengineering, University of California, Berkeley, Berkeley, CA 94720, USA.

⁷Department of Electrical Engineering and Computer Science, University of California, Berkeley, Berkeley, CA 94720, USA.

⁸Department of Biophysics, Institute of Quantum Biophysics, Sungkyunkwan University, Suwon, Korea.

⁹Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, Korea.

¹⁰These authors contributed equally: Mengxi Wu, Zhiteng Ma.

Corresponding authors

Correspondence to Jean Kwun, Luke P. Lee or Tony Jun Huang.

Abstract

Therapeutic apheresis aims to selectively remove pathogenic substances, such as antibodies that trigger various symptoms and diseases. Unfortunately, current apheresis devices cannot handle small blood volumes in infants or small animals, hindering the testing of animal model advancements. This limitation restricts our ability to provide treatment options for particularly susceptible infants and children with limited therapeutic alternatives. Here, we report our solution to these challenges through an acoustofluidic-based therapeutic apheresis system designed for processing small blood volumes. Our design integrates an acoustofluidic device with a fluidic stabilizer array on a chip, separating blood components from minimal extracorporeal volumes. We carried out plasma apheresis in mouse models, each with a blood volume of just 280 μL. Additionally, we achieved successful plasmapheresis in a sensitized mouse, significantly lowering preformed donor-specific antibodies and enabling desensitization in a transplantation model. Our system offers a new solution for small-sized subjects, filling a critical gap in existing technologies and providing potential benefits for a wide range of patients.

논문정보

형식Research article
게재일2024년 08월 (BRIC 등록일 2024-08-12)
연구진국내(교신)+국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기